Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Inclusion Criteria:

* The subject has histologically confirmed diagnosis at any time of grade IV astrocytic tumor as determined by the investigator. Tumor samples will be required for pathology review.
* The subject has received prior standard radiation for any grade astrocytic tumor.
* The subject has received prior temozolomide (Temodar) therapy
* The subject has had one or two progressions as grade IV astrocytic tumor from any grade, as determined by investigator
* The subject must have a qualifying brain MRI scan within a specific timeframe prior to start of study treatment
* For subjects with recent tumor resection or biopsy, starting on study must occur a specified amount of time after the surgery and the subject must have recovered from the effects of surgery
* The subject has a Karnofsky Performance Status ≥ 70% and has the ability to swallow whole capsules
* The subject is capable of understanding the informed consent and has signed the informed consent document
* The subject has adequate organ and marrow function
* Sexually active subjects (male and female) must agree to use medically accepted methods of contraception during the course of the study and for 6 months following discontinuation of study treatment
* The subject has had no other diagnosis of malignancy (certain exceptions apply)
* Female subjects of childbearing potential must have a negative pregnancy test at screening

Exclusion Criteria:

* The subject has received certain prior anticancer therapies within a certain amount of time before starting study treatment
* The subject is receiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin
* The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or CT scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible
* The subject is unable to undergo MRI scan (eg, has pacemaker)
* The subject has received enzyme-inducing anti-epileptic agents within a certain time prior to starting study treatment (eg, carbamazepine, phenytoin, phenobarbital, primidone)
* The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Grade ≤ 1 from AEs (except alopecia and lymphopenia) due to surgery, or other medications that were administered prior to study start
* The subject has evidence of unhealed wounds
* The subject is pregnant or breast-feeding
* The subject has serious intercurrent illness or a recent history of serious disease
* The subject has inherited bleeding diathesis or coagulopathy (disease affecting how blood clots) with the risk of bleeding
* The subject has a history of any medical or surgical conditions (eg, stomach or intestinal surgery or resection) that would potentially interfere with or alter gastrointestinal function
* The subject has a history of idiopathic pulmonary fibrosis or interstitial lung disease
* The subject has received any live virus vaccine or any inactivated vaccine within a certain amount of time before starting study treatment